Literature DB >> 17416210

Psychosis: atypical limbic epilepsy versus limbic hyperexcitability with onset at puberty?

Frank R Sharp1, Robert L Hendren.   

Abstract

Phencyclidine (PCP), ketamine (Special K), and MK-801 are noncompetitive N-methyl-d-aspartate (NMDA) antagonists that produce acute psychosis in humans. The psychosis produced by these psychomimetic drugs is indistinguishable from schizophrenia and includes both positive and negative symptoms. This drug-induced psychosis occurs after puberty in humans. On the basis of the MK-801-induced spike-and-wave activity in rats and increased blood flow and metabolism in brain of patients with psychosis caused by these psychomimetics, this brief review argues that this psychosis is an atypical form of limbic epilepsy. Moreover, there is a specific limbic thalamcortical psychosis circuit that mediates cell injury in limbic cortex of rodents and may mediate this PCP-induced psychosis in humans. It is proposed that this thalamocortical psychosis circuit develops at puberty and can mediate PCP and ketamine-mediated psychosis and possibly the psychosis of schizophrenia, bipolar disease and other disorders that have their onset at puberty. Finally, based on this developmentally regulated psychosis/epilepsy-related thalamocortical circuitry, it is proposed that antiepileptic drugs that promote GABAergic mechanisms may decrease the probability of episodic psychosis from any cause.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17416210      PMCID: PMC2680611          DOI: 10.1016/j.yebeh.2007.02.014

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  42 in total

Review 1.  Psychosis: pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia?

Authors:  F R Sharp; M Tomitaka; M Bernaudin; S Tomitaka
Journal:  Trends Neurosci       Date:  2001-06       Impact factor: 13.837

Review 2.  Competitive AMPA receptor antagonists.

Authors:  Daniela Catarzi; Vittoria Colotta; Flavia Varano
Journal:  Med Res Rev       Date:  2007-03       Impact factor: 12.944

Review 3.  Anticonvulsants in bipolar disorder.

Authors:  Charles L Bowden; Nancy U Karren
Journal:  Aust N Z J Psychiatry       Date:  2006-05       Impact factor: 5.744

4.  Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers.

Authors:  A Breier; A K Malhotra; D A Pinals; N I Weisenfeld; D Pickar
Journal:  Am J Psychiatry       Date:  1997-06       Impact factor: 18.112

Review 5.  Schizophrenia and glutamatergic transmission.

Authors:  C A Tamminga
Journal:  Crit Rev Neurobiol       Date:  1998

Review 6.  NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders.

Authors:  J H Krystal; D C D'Souza; I L Petrakis; A Belger; R M Berman; D S Charney; W Abi-Saab; S Madonick
Journal:  Harv Rev Psychiatry       Date:  1999 Sep-Oct       Impact factor: 3.732

7.  Bilateral blockade of NMDA receptors in anterior thalamus by dizocilpine (MK-801) injures pyramidal neurons in rat retrosplenial cortex.

Authors:  S Tomitaka; M Tomitaka; B K Tolliver; F R Sharp
Journal:  Eur J Neurosci       Date:  2000-04       Impact factor: 3.386

8.  Neuronal injury produced by NMDA antagonists can be detected using heat shock proteins and can be blocked with antipsychotics.

Authors:  F R Sharp; M Butman; K Aardalen; J Nickolenko; R Nakki; S M Massa; R A Swanson; S M Sagar
Journal:  Psychopharmacol Bull       Date:  1994

9.  Effect of age and sex on N-methyl-D-aspartate antagonist-induced neuronal necrosis in rats.

Authors:  R N Auer
Journal:  Stroke       Date:  1996-04       Impact factor: 7.914

10.  NMDA antagonist neurotoxicity: mechanism and prevention.

Authors:  J W Olney; J Labruyere; G Wang; D F Wozniak; M T Price; M A Sesma
Journal:  Science       Date:  1991-12-06       Impact factor: 47.728

View more
  7 in total

1.  NMDAR antagonist action in thalamus imposes δ oscillations on the hippocampus.

Authors:  Yuchun Zhang; Takashi Yoshida; Donald B Katz; John E Lisman
Journal:  J Neurophysiol       Date:  2012-03-14       Impact factor: 2.714

2.  Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity.

Authors:  C Hammer; B Stepniak; A Schneider; S Papiol; M Tantra; M Begemann; A-L Sirén; L A Pardo; S Sperling; S Mohd Jofrry; A Gurvich; N Jensen; K Ostmeier; F Lühder; C Probst; H Martens; M Gillis; G Saher; F Assogna; G Spalletta; W Stöcker; T F Schulz; K-A Nave; H Ehrenreich
Journal:  Mol Psychiatry       Date:  2013-09-03       Impact factor: 15.992

Review 3.  Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia.

Authors:  John E Lisman; Joseph T Coyle; Robert W Green; Daniel C Javitt; Francine M Benes; Stephan Heckers; Anthony A Grace
Journal:  Trends Neurosci       Date:  2008-04-07       Impact factor: 13.837

4.  Ketamine: NMDA Receptors and Beyond.

Authors:  Charles F Zorumski; Yukitoshi Izumi; Steven Mennerick
Journal:  J Neurosci       Date:  2016-11-02       Impact factor: 6.167

Review 5.  Delta frequency optogenetic stimulation of the thalamic nucleus reuniens is sufficient to produce working memory deficits: relevance to schizophrenia.

Authors:  Aranda R Duan; Carmen Varela; Yuchun Zhang; Yinghua Shen; Lealia Xiong; Matthew A Wilson; John Lisman
Journal:  Biol Psychiatry       Date:  2015-02-28       Impact factor: 13.382

6.  Control of neuronal ion channel function by glycogen synthase kinase-3: new prospective for an old kinase.

Authors:  Norelle C Wildburger; Fernanda Laezza
Journal:  Front Mol Neurosci       Date:  2012-07-16       Impact factor: 5.639

7.  Curative Effect of Aqueous Leaf Extract of Crinum Giganteum on NMDA-Receptor Antagonist-Induced Schizophrenic Wistar Rat Model.

Authors:  Elizabeth Finbarrs-Bello; Emmanuel Nebeuwa Obikili; Esom Emmanuel Anayochukwu; Anyanwu Emeka Godson
Journal:  Open Access Maced J Med Sci       Date:  2016-08-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.